Literature DB >> 9882338

Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element into a GABP binding site.

K Verhoef1, R W Sanders, V Fontaine, S Kitajima, B Berkhout.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) transcription is regulated by the viral Tat protein and cellular factors, of which the concentration and activity may depend on the cell type. Viral long terminal repeat (LTR) promoter sequences are therefore optimized to suit the specific nuclear environment of the target host cell. In long-term cultures of a Tat-defective, poorly replicating HIV-1 mutant, we selected for a faster-replicating virus with a 1-nucleotide deletion in the upstream copy of two highly conserved NF-kappaB binding sites. The variant enhancer sequence demonstrated a severe loss of NF-kappaB binding in protein binding assays. Interestingly, we observed a new binding activity that is specific for the variant NF-kappaB sequence and is present in the nuclear extract of unstimulated cells that lack NF-kappaB. These results suggest that inactivation of the NF-kappaB site coincides with binding of another transcription factor. Fine mapping of the sequence requirements for binding of this factor revealed a core sequence similar to that of Ets binding sites, and supershift assays with antibodies demonstrated the involvement of the GABP transcription factor. Transient transfection experiments with LTR-chloramphenicol acetyltransferase constructs indicated that the variant LTR promoter is specifically inhibited by GABP in the absence of Tat, but this promoter was dramatically more responsive to Tat than the wild-type LTR. Introduction of this GABP site into the LAI virus yielded a specific gain of fitness in SupT1 cells, which contain little NF-kappaB protein. These results suggest that GABP potentiates Tat-mediated activation of LTR transcription and viral replication in some cell types. Conversion of an NF-kappaB into a GABP binding site is likely to have occurred also during the worldwide spread of HIV-1, as we noticed the same LTR modification in subtype E isolates from Thailand. This typical LTR promoter configuration may provide these viruses with unique biological properties.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882338      PMCID: PMC103957     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

Review 1.  Virus-host interactions and the pathogenesis of murine and human oncogenic retroviruses.

Authors:  P N Tsichlis; P A Lazo
Journal:  Curr Top Microbiol Immunol       Date:  1991       Impact factor: 4.291

2.  Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups.

Authors:  M T Dittmar; G Simmons; S Hibbitts; M O'Hare; S Louisirirotchanakul; S Beddows; J Weber; P R Clapham; R A Weiss
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Oncogene activation of HIV-LTR-driven expression via the NF-kappa B binding sites.

Authors:  J T Bruder; G Heidecker; T H Tan; J C Weske; D Derse; U R Rapp
Journal:  Nucleic Acids Res       Date:  1993-11-11       Impact factor: 16.971

Review 4.  Gene regulation by Ets proteins.

Authors:  R Janknecht; A Nordheim
Journal:  Biochim Biophys Acta       Date:  1993-12-23

5.  A novel Ets-related transcription factor, Elf-1, binds to human immunodeficiency virus type 2 regulatory elements that are required for inducible trans activation in T cells.

Authors:  J M Leiden; C Y Wang; B Petryniak; D M Markovitz; G J Nabel; C B Thompson
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

6.  Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation.

Authors:  C Kunsch; S M Ruben; C A Rosen
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

7.  Identification of Ets- and notch-related subunits in GA binding protein.

Authors:  K LaMarco; C C Thompson; B P Byers; E M Walton; S L McKnight
Journal:  Science       Date:  1991-08-16       Impact factor: 47.728

8.  Protein interactions with DNA elements in variant equine infectious anemia virus enhancers and their impact on transcriptional activity.

Authors:  M Carvalho; M Kirkland; D Derse
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Activation of the human immunodeficiency virus type 2 enhancer is dependent on purine box and kappa B regulatory elements.

Authors:  D M Markovitz; M J Smith; J Hilfinger; M C Hannibal; B Petryniak; G J Nabel
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

10.  Synergistic activation of the HTLV1 LTR Ets-responsive region by transcription factors Ets1 and Sp1.

Authors:  A Gégonne; R Bosselut; R A Bailly; J Ghysdael
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

View more
  35 in total

Review 1.  Hostile takeovers: viral appropriation of the NF-kappaB pathway.

Authors:  J Hiscott; H Kwon; P Génin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Effects of random mutations in the human immunodeficiency virus type 1 transcriptional promoter on viral fitness in different host cell environments.

Authors:  Tim van Opijnen; Maarten C Boerlijst; Ben Berkhout
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection.

Authors:  Alexandra Duverger; Frank Wolschendorf; Mingce Zhang; Fredric Wagner; Brandon Hatcher; Jennifer Jones; Randall Q Cron; Renee M van der Sluis; Rienk E Jeeninga; Ben Berkhout; Olaf Kutsch
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

4.  Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.

Authors:  Yan Desfosses; Mayra Solis; Qiang Sun; Nathalie Grandvaux; Carine Van Lint; Arsene Burny; Anne Gatignol; Mark A Wainberg; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Caveolin-1 suppresses human immunodeficiency virus-1 replication by inhibiting acetylation of NF-κB.

Authors:  Glenn E Simmons; Harry E Taylor; James E K Hildreth
Journal:  Virology       Date:  2012-06-28       Impact factor: 3.616

6.  Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism.

Authors:  Wendy Maury; Robert J Thompson; Quentin Jones; Sarahann Bradley; Tara Denke; Prasith Baccam; Matthew Smazik; J Lindsay Oaks
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 7.  Recent advances on viral manipulation of NF-κB signaling pathway.

Authors:  Jun Zhao; Shanping He; Arlet Minassian; Junhua Li; Pinghui Feng
Journal:  Curr Opin Virol       Date:  2015-09-15       Impact factor: 7.090

8.  The ETS transcription factor GABPalpha is essential for early embryogenesis.

Authors:  Sika Ristevski; Debra A O'Leary; Anders P Thornell; Michael J Owen; Ismail Kola; Paul J Hertzog
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

9.  The human immunodeficiency virus type 1 promoter contains a CATA box instead of a TATA box for optimal transcription and replication.

Authors:  Tim van Opijnen; Joost Kamoschinski; Rienk E Jeeninga; Ben Berkhout
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner.

Authors:  Tim van Opijnen; Rienk E Jeeninga; Maarten C Boerlijst; Georgios P Pollakis; Veera Zetterberg; Mika Salminen; Ben Berkhout
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.